plus a chance to lead the ILT2 field. The companies already wrapped up a phase 1 dose-escalation study weighing BND-22 as a monotherapy and in combination with Keytruda, plus Eli Lilly and Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback